Who Generates More Revenue? Alnylam Pharmaceuticals, Inc. or Dynavax Technologies Corporation

Biotech Giants: Alnylam vs. Dynavax Revenue Battle

__timestampAlnylam Pharmaceuticals, Inc.Dynavax Technologies Corporation
Wednesday, January 1, 20145056100011032000
Thursday, January 1, 2015410970004050000
Friday, January 1, 20164715900011043000
Sunday, January 1, 201789912000327000
Monday, January 1, 2018749080008198000
Tuesday, January 1, 201921975000035219000
Wednesday, January 1, 202049285300046551000
Friday, January 1, 2021844287000439442000
Saturday, January 1, 20221037418000722683000
Sunday, January 1, 20231828292000232284000
Monday, January 1, 20242248243000
Loading chart...

Unlocking the unknown

Revenue Race: Alnylam vs. Dynavax

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Alnylam Pharmaceuticals, Inc. and Dynavax Technologies Corporation have been at the forefront of this race since 2014. Alnylam has consistently outperformed Dynavax, with a staggering 3,500% increase in revenue from 2014 to 2023. In contrast, Dynavax saw a more modest growth of around 2,000% over the same period.

A Decade of Growth

Alnylam's revenue surged from approximately $50 million in 2014 to nearly $1.8 billion in 2023, showcasing its robust growth trajectory. Meanwhile, Dynavax's revenue peaked at around $723 million in 2022, before dropping to $232 million in 2023. This fluctuation highlights the volatile nature of the biotech industry.

The Future Outlook

As both companies continue to innovate, the revenue gap may narrow. Investors and industry watchers should keep a close eye on their strategic moves in the coming years.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025